ECSP14013132A - Anticuerpos anti-psgl-1 y usos de los mismos - Google Patents

Anticuerpos anti-psgl-1 y usos de los mismos

Info

Publication number
ECSP14013132A
ECSP14013132A ECSP14013132A ECSP14013132A EC SP14013132 A ECSP14013132 A EC SP14013132A EC SP14013132 A ECSP14013132 A EC SP14013132A EC SP14013132 A ECSP14013132 A EC SP14013132A
Authority
EC
Ecuador
Prior art keywords
antibodies
psgl
same
cells
here
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjaya Singh
Tobias Litzenburger
Stefan Bassarab
Barbara Enenkel
Patrick Garidel
Heidrun Schott
Original Assignee
Abgenomics Cooperatief Ua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Cooperatief Ua filed Critical Abgenomics Cooperatief Ua
Publication of ECSP14013132A publication Critical patent/ECSP14013132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Aquí se proporciona, en un aspecto, anticuerpos que se unen inmunoespecíficamente a PSGL-1, polinucleótidos que comprenden secuencias de nucleótido que codifican a tales anticuerpos, y los vectores de expresión y células huésped para producir a tales anticuerpos. También se proveen aquí los kits y las composiciones farmacéuticas que comprenden los anticuerpos que se unen específicamente a PSGL-1, así como los métodos para tratar un desorden o enfermedad causado por o asociado con la proliferación aumentada y/o cantidades aumentadas de células T activadas usando los anticuerpos aquí descritos.
ECSP14013132 2011-06-13 2014-01-13 Anticuerpos anti-psgl-1 y usos de los mismos ECSP14013132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161496249P 2011-06-13 2011-06-13

Publications (1)

Publication Number Publication Date
ECSP14013132A true ECSP14013132A (es) 2015-04-30

Family

ID=47357432

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013132 ECSP14013132A (es) 2011-06-13 2014-01-13 Anticuerpos anti-psgl-1 y usos de los mismos

Country Status (21)

Country Link
US (4) US20130209449A9 (es)
EP (2) EP3925978A1 (es)
JP (1) JP6180408B2 (es)
KR (1) KR102103036B1 (es)
CN (3) CN116063522A (es)
AU (1) AU2012271845B2 (es)
BR (1) BR112013031892A2 (es)
CA (1) CA2838952C (es)
CL (1) CL2013003570A1 (es)
CO (1) CO6940376A2 (es)
EC (1) ECSP14013132A (es)
IL (2) IL229844B (es)
MX (1) MX358447B (es)
NZ (1) NZ619524A (es)
PH (1) PH12013502568B1 (es)
RU (1) RU2650817C2 (es)
SG (1) SG10201604767TA (es)
TW (1) TWI643872B (es)
UA (1) UA114712C2 (es)
WO (1) WO2012174001A1 (es)
ZA (1) ZA201400209B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
NZ551625A (en) 2004-05-11 2011-03-31 Abgenomics Cooperatief Ua T-cell death-inducing epitopes
KR102103036B1 (ko) 2011-06-13 2020-04-22 압제노믹스 코오페라티에프 유.에이. 항-ｐｓｇｌ-１ 항체 및 그의 용도
CN106659784B (zh) * 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 Psgl-1调控剂及其用途
RU2766000C2 (ru) 2016-01-08 2022-02-07 АльтруБио Инк. Четырехвалентные антитела к psgl-1 и их применения
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
KR20230132603A (ko) 2017-01-11 2023-09-15 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
CA3054067A1 (en) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
AU2020288823A1 (en) 2019-06-04 2022-02-03 Verseau Therapeutics, Inc. Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
WO2021234160A2 (en) * 2020-05-22 2021-11-25 Formycon Ag Ace2 fusion proteins and uses thereof
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途
US12290565B2 (en) 2021-11-17 2025-05-06 Altrubio Inc. Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers
CN120265323A (zh) * 2022-09-13 2025-07-04 泰克斯制药公司 抗体、组合物和治疗方法
TW202540180A (zh) * 2023-11-17 2025-10-16 美商美國全心醫藥生技股份有限公司 抗psgl-1抗體及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
CA2130173A1 (en) 1992-03-17 1993-09-30 Norman Hardman Genetically engineered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
NZ261991A (en) 1993-01-25 1998-04-27 Dana Farber Cancer Inst Inc Chimeric l and p selectin made by exchange of domains, uses thereof
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
ATE251636T1 (de) 1995-08-03 2003-10-15 Univ Oklahoma O-glycaninhibitoren von selectinvermittelten entzüngen
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
AU774419C (en) 1998-10-30 2005-03-03 Genetics Institute, Llc Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
AU6173501A (en) 2000-05-19 2001-12-03 Blood Res Center Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
EP1325123A4 (en) 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
US20040002450A1 (en) 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
HUP0700079A2 (en) 2000-12-29 2007-05-02 Savient Pharmaceuticals Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
MXPA05000272A (es) 2002-07-01 2005-09-20 Savient Pharmaceuticals Inc Anticuerpos y usos de ellos.
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
CA2531283A1 (en) 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
ES2397631T3 (es) * 2003-12-25 2013-03-08 Kyowa Hakko Kirin Co., Ltd. Mutante antagonista de anticuerpos ANTI-CD40
EP1720996A4 (en) * 2004-02-13 2007-03-21 Immunomedics Inc RECOMBINANT CYTOTOXIC RASES CONTAINING FUSION PROTEINS
CN1942483B (zh) * 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
NZ551625A (en) 2004-05-11 2011-03-31 Abgenomics Cooperatief Ua T-cell death-inducing epitopes
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
PL2468770T3 (pl) * 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
RU2500686C2 (ru) * 2007-03-22 2013-12-10 Дженентек, Инк. АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE
EP2139924B1 (en) * 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
EP2666787B1 (en) * 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
AU2008262384B9 (en) 2007-06-05 2014-11-27 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
WO2009032145A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110086366A1 (en) * 2008-02-22 2011-04-14 Genmab A/S Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
WO2009140623A2 (en) * 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
US20100233157A1 (en) * 2009-03-12 2010-09-16 Osorio Lyda M Human antibodies against human fas and their use
EA201270228A1 (ru) * 2009-07-31 2012-09-28 Медарекс, Инк. Полноценные человеческие антитела к btla
KR102103036B1 (ko) 2011-06-13 2020-04-22 압제노믹스 코오페라티에프 유.에이. 항-ｐｓｇｌ-１ 항체 및 그의 용도
WO2015195904A1 (en) 2014-06-20 2015-12-23 Abgenomics International Inc. Her2 antibody-drug conjugates

Also Published As

Publication number Publication date
US20130209449A9 (en) 2013-08-15
EP3925978A1 (en) 2021-12-22
AU2012271845B2 (en) 2017-07-27
CO6940376A2 (es) 2014-05-09
NZ619524A (en) 2016-10-28
KR102103036B1 (ko) 2020-04-22
US20130251708A1 (en) 2013-09-26
JP2014519524A (ja) 2014-08-14
AU2012271845A1 (en) 2014-01-23
KR20140066153A (ko) 2014-05-30
ZA201400209B (en) 2020-05-27
US20130011391A1 (en) 2013-01-10
IL287270A (en) 2021-12-01
PH12013502568A1 (en) 2014-01-27
CN116063522A (zh) 2023-05-05
IL229844B (en) 2022-02-01
EP2718325A1 (en) 2014-04-16
PH12013502568B1 (en) 2018-08-10
CA2838952C (en) 2020-11-24
EP2718325A4 (en) 2015-03-11
CL2013003570A1 (es) 2014-08-22
MX2013014814A (es) 2014-07-22
BR112013031892A2 (pt) 2016-11-22
US20240124604A1 (en) 2024-04-18
RU2650817C2 (ru) 2018-04-17
CN108892726A (zh) 2018-11-27
US11897964B2 (en) 2024-02-13
CA2838952A1 (en) 2012-12-20
SG10201604767TA (en) 2016-08-30
CN103732626A (zh) 2014-04-16
TW201302791A (zh) 2013-01-16
US20210395383A1 (en) 2021-12-23
TWI643872B (zh) 2018-12-11
WO2012174001A1 (en) 2012-12-20
MX358447B (es) 2018-08-21
UA114712C2 (uk) 2017-07-25
RU2013158083A (ru) 2015-09-20
JP6180408B2 (ja) 2017-08-16

Similar Documents

Publication Publication Date Title
ECSP14013132A (es) Anticuerpos anti-psgl-1 y usos de los mismos
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
MX2015000999A (es) Anticuerpos anti kit y usos de los mismos.
CU20140091A7 (es) Compuestos de imidazopirrolidinona
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
AR091837A1 (es) Compuestos para inmunoterapia dirigida
AR088171A1 (es) Anticuerpos anti-erbb3 y usos de los mismos
MX381724B (es) Cadenas ligeras comunes y metodos de uso.
AR094896A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2014003355A1 (es) Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
AR090056A1 (es) Anticuerpos anti-cxcr3
EA202190619A1 (ru) Противовирусные соединения
MX2014003979A (es) Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos.
CR20150370A (es) Compuestos antivirales
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
MX366296B (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AR087608A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
UY33931A (es) Agentes de union biespecificos
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
MX2016016992A (es) Aptameros especificos de tlr-4 y usos de los mismos.
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.